THRD Stock Overview
A biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Third Harmonic Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.93 |
| 52 Week High | US$16.94 |
| 52 Week Low | US$4.51 |
| Beta | 0 |
| 1 Month Change | 28.15% |
| 3 Month Change | 52.50% |
| 1 Year Change | 190.47% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -24.14% |
Recent News & Updates
Recent updates
Here's Why We're Not At All Concerned With Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Situation
Apr 06
We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely
Sep 06We're Hopeful That Third Harmonic Bio (NASDAQ:THRD) Will Use Its Cash Wisely
May 02We're Not Very Worried About Third Harmonic Bio's (NASDAQ:THRD) Cash Burn Rate
Dec 16Shareholder Returns
| THRD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 15.6% | 0.5% | -0.2% |
| 1Y | 190.5% | 17.9% | 28.2% |
Return vs Industry: THRD exceeded the US Pharmaceuticals industry which returned 16.7% over the past year.
Return vs Market: THRD exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| THRD volatility | |
|---|---|
| THRD Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: THRD's share price has been volatile over the past 3 months.
Volatility Over Time: THRD's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 31 | Natalie Holles | www.thirdharmonicbio.com |
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions.
Third Harmonic Bio, Inc. Fundamentals Summary
| THRD fundamental statistics | |
|---|---|
| Market cap | US$636.35m |
| Earnings (TTM) | -US$29.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-20.7x
P/E RatioIs THRD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THRD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.60m |
| Earnings | -US$29.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did THRD perform over the long term?
See historical performance and comparison